Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2019 01:00 ET | Source: argenx SE

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn ...
December 03, 2018 01:00 ET | Source: argenx SE

argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

Regulated information – Inside information Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion potentiallyJanssen to pay argenx...
December 03, 2018 01:00 ET | Source: argenx SE

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events ITP program expected to advance to Phase 3 with IV efgartigimod...
November 01, 2018 09:15 ET | Source: argenx SE

argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition

Regulated information – Inside information 92% overall response rate with durability up to 14.4 months in ongoing analysis of Phase 1/2 trial Updated results from Phase 1/2 trial of...
October 25, 2018 01:00 ET | Source: argenx SE

argenx reports third quarter 2018 financial results and provides business update

October 25, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based...
October 09, 2018 01:00 ET | Source: argenx SE

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

October 9, 2018Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based...
September 21, 2018 16:00 ET | Source: argenx SE

argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Regulated information September 21,...
September 18, 2018 20:45 ET | Source: argenx SE

argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Regulated information - Inside...
September 17, 2018 16:20 ET | Source: argenx SE

argenx announces launch of proposed public offering in the United States

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Regulated information - Inside...
September 17, 2018 01:00 ET | Source: argenx SE

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Favorable safety and tolerability...